Get the Stockscreener App
2.69
0.74%
-0.02
After Hours:
2.70
0.01
+0.37%
Editas Medicine Inc stock is traded at $2.69, with a volume of 1.10M.
It is down -0.74% in the last 24 hours and up +17.47% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$2.71
Open:
$2.72
24h Volume:
1.10M
Relative Volume:
0.47
Market Cap:
$241.89M
Revenue:
$32.31M
Net Income/Loss:
$-237.09M
P/E Ratio:
-0.934
EPS:
-2.88
Net Cash Flow:
$-219.11M
1W Performance:
-2.54%
1M Performance:
+17.47%
6M Performance:
+78.15%
1Y Performance:
-28.27%
1-Day Range:
$2.6501
$2.74
1-Week Range:
$2.555
$2.84
52-Week Range:
$0.9101
$4.12
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.69 | 230.20M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Ieq Capital LLC Increases Stake in Editas Medicine, Inc. $EDIT - MarketBeat
Nuveen LLC Makes New Investment in Editas Medicine, Inc. $EDIT - MarketBeat
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? - sharewise.com
Editas Medicine Q3 EPS Estimate Increased by Zacks Research - MarketBeat
Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 26% - 富途牛牛
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry - simplywall.st
Wells Fargo & Company Issues Positive Forecast for Editas Medicine (NASDAQ:EDIT) Stock Price - MarketBeat
Editas Medicine price target raised to $4 from $3 at Wells Fargo - MSN
Is Editas Medicine Inc. a good stock for dollar cost averagingJuly 2025 Momentum & AI Driven Stock Price Forecasts - 뉴스영
Editas Medicine Bets On Next-Gen Gene Editing - Finimize
Statistical indicators supporting Editas Medicine Inc.’s strengthRate Hike & AI Driven Stock Reports - Newser
Using portfolio simulators with Editas Medicine Inc. includedJuly 2025 Sector Moves & Growth Focused Entry Reports - Newser
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NOVN) and Editas Medicine (EDIT) - The Globe and Mail
What drives Editas Medicine Inc.’s stock price2025 Top Gainers & Capital Efficient Trading Techniques - خودرو بانک
What are Editas Medicine Inc.’s technical support levelsJuly 2025 Outlook & High Return Stock Watch Alerts - خودرو بانک
Can Editas Medicine Inc. weather a recession2025 Year in Review & Verified Technical Signals - خودرو بانک
Is Editas Medicine Inc. a momentum stockJuly 2025 Recap & Accurate Intraday Trade Tips - خودرو بانک
Can Editas Medicine Inc. expand into new marketsWeekly Stock Report & Weekly Consistent Profit Watchlists - خودرو بانک
Predicting Editas Medicine Inc. trend using moving averages2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - Newser
Volatility Watch: Is Editas Medicine Inc. stock influenced by commodity prices2025 Technical Patterns & Detailed Earnings Play Strategies - خودرو بانک
Is Editas Medicine Inc. forming a bottoming baseQuarterly Profit Summary & Safe Capital Growth Stock Tips - Newser
Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating - AInvest
Using Ichimoku Cloud for Editas Medicine Inc. technicalsWeekly Investment Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Editas Medicine Inc. stock ready for a breakoutJuly 2025 Big Picture & Smart Investment Allocation Tips - Newser
Real time scanner hits for Editas Medicine Inc. explainedMarket Weekly Review & Low Drawdown Trading Techniques - Newser
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
How to escape a deep drawdown in Editas Medicine Inc.2025 Stock Rankings & Free Verified High Yield Trade Plans - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.10 Consensus Target Price from Analysts - MarketBeat
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience - Investing.com
Can volume confirm reversal in Editas Medicine Inc.Quarterly Earnings Report & Free Fast Gain Swing Trade Alerts - Newser
Using data models to predict Editas Medicine Inc. stock movementPortfolio Return Report & Low Risk High Reward Trade Ideas - Newser
Is Editas Medicine Inc. stock entering bullish territoryPortfolio Risk Report & Reliable Price Action Trade Plans - Newser
How to build a custom watchlist for Editas Medicine Inc.Recession Risk & AI Forecast Swing Trade Picks - Newser
Is Editas Medicine Inc. showing signs of accumulation2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol - Zacks Investment Research
Evaluating Editas Medicine Inc. with trendline analysisQuarterly Profit Summary & Consistent Growth Stock Picks - Newser
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $4 to $4 - 富途牛牛
Editas Medicine at Wells Fargo Conference: Gene Editing Milestone - Investing.com
Activity Recap: How does Editas Medicine Inc. score in quality rankingsDay Trade & Free Accurate Trade Setup Notifications - خودرو بانک
what the charts say about editas medicine inc. todayQuarterly Profit Summary & Smart Allocation Stock Reports - Newser
Is now the right time to enter Editas Medicine Inc.Dividend Hike & Low Drawdown Investment Ideas - خودرو بانک
How to track smart money flows in Editas Medicine Inc.Weekly Trade Review & Verified Technical Signals - Newser
Is it time to cut losses on Editas Medicine Inc.2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Is Editas Medicine Inc. forming a reversal patternTrade Volume Summary & Weekly Stock Breakout Alerts - Newser
What machine learning models say about Editas Medicine Inc.Weekly Stock Report & High Accuracy Swing Trade Signals - Newser
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):